With over 20 years of expertise in cardiovascular and respiratory data analysis, safety pharmacology, and GLP compliance, Dr. Ray Chui delivers precise, regulatory-compliant solutions for preclinical research.

Endpoint Preclinical is proud to welcome Dr. Ray Chui, PhD, DSP, to our Expert Network. As the co-founder of Cardiovascular Analytics (CVA), Dr. Chui specializes in cardiovascular and respiratory data analysis, offering end-to-end solutions that include data interpretation, reporting, and regulatory compliance for GLP and non-GLP studies. His work supports safety pharmacology, toxicology, and efficacy assessments, providing actionable insights to drive preclinical drug development. View Ray’s Profile

Cardiovascular and Respiratory Data Analysis: Dr. Chui’s expertise lies in processing and interpreting complex data from a variety of preclinical models. Key capabilities include:

• ECG Analysis: Comprehensive evaluation of PR, QRS, QT, and QTc intervals, as well as arrhythmia detection and heart rate variability.
• Respiratory Analysis: Assessment of tidal volume, respiratory rate, and minute ventilation, integrated with cardiovascular data for a complete cardiorespiratory profile.
• Multimodal Data Formats: Proficiency in handling data from systems such as EMKA ecgAUTO, DSI Ponemah, and other acquisition platforms, ensuring flexible and comprehensive analysis.

GLP Compliance and Regulatory Reporting: Dr. Chui is adept at navigating GLP requirements for safety pharmacology studies, providing:

• Validated Systems and Software: Ensuring data integrity and compliance with regulatory standards.
• Comprehensive Reporting: Delivering GLP-compliant reports with industry-leading turnaround times, tailored to meet specific regulatory and client requirements.

Biostatistics and Advanced Analytics: Leveraging tools like SAS and Prism, Dr. Chui together with his business partner Joel Baublits, applies robust statistical methods to generate precise, reproducible results for:

• Safety and Toxicology Studies: Detection of arrhythmias, conduction abnormalities, and respiratory irregularities.
• Efficacy Assessments: Quantitative and qualitative analysis of pharmacologic interventions.

Dr. Chui emphasizes rigorous data analysis and timely reporting, ensuring clients receive:

• Regulatory-Ready Data: Reports aligned with S7B/E14 guidance for cardiac safety pharmacology.
• Integrated Insights: Comprehensive evaluations that combine cardiovascular and respiratory endpoints for informed decision-making.

Dr. Chui’s expertise supports a wide range of preclinical research, including:

• Safety Pharmacology: Evaluating cardiac and respiratory safety of new therapeutics.
• Toxicology Studies: Providing robust data for regulatory submissions.
• Efficacy Research: Assessing the impact of interventions on cardiorespiratory function in preclinical models.

Join us in welcoming Dr. Ray Chui to Endpoint Preclinical. His expertise in cardiovascular and respiratory data analytics strengthens our ability to deliver high-quality, regulatory-compliant solutions for clients worldwide. Contact us to learn how Dr. Chui can support your preclinical research needs.